1. Шарапова О.В. Письмо МЗ РФ 11 апреля 2003 г. №2510/3797-03-32.
2. Назаренко Т.А.,  Дуринян Э.Р., Чечурова Т.Н. Эндокринное бесплодие у женщин.  Диагностика и лечение. М., 2004.
3. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006; 3: CD001750.
4. Руководство ВОЗ по стандартизованному обследованию и диагностике бесплодных супружеских пар. М.: МЕДпресс, 1997.
5. Кулаков В.И., Корнеева И.Е.  Диагностика и лечение женского бесплодия. В кн.: Практическая гинекология. Под ред. В.И.Кулакова. М., 2002.
6. Verhaak CM, Smeenk JM, van Minnen A et al. A longitudinal, prospective study on emotional adjustment before, during and after consecutive fertility treatment cycles. Hum Reprod 2005; 20: 2253–60.
7. Fauser BC, Devroey P. Why is the clinical acceptance of gonadotropinreleasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 2005; 83: 1607–11.
8. Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians’ second choice? Data from the German national IVF registry. Hum Reprod 2005; 20: 2373–5.
9. River J, Jiang JC, Lahrichi SL et al. Dose relationship between GnRH antagonists and pituitary suppression – GnRH analogues and Reproductive Medicine. Eds. R.G.Edwards, H.Beard, J.P.W.Vermeiden. Hum Reprod 1996; 11 (Suppl. 3): 133–47.
10. Rabinovici J, Rothman P, Monroe SE et al. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. JCEM 1992; 75: 1220–5.
11. Hsueh AJ, Jones PB. Extrapituitary actions of gonadotropin releasing hormone. Endocrinol Rev 1981; 2: 437–61.
12. The ganirelix dose-finding study group. A double-blind, randomized, dose-finding study to assess the efficacy of the GnRH antagonist ganirelix (Org 37642) to prevent premature LH surges in women undergoing controlled ovarian hyperstimulation with recombinant FSH (Puregon). Hum Reprod 1998; 13: 3023–31.
13. Marcus HJ, Marcus DM, Marcus SF. How do infertile couples choose their IVF centers? An internet-based survey. Fertil Steril 2005; 83: 779–81.
14. Lambalk CB, Leader A, Olivennes F et al. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. Hum Reprod 2006; 21: 632–9.
15. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a cochrane review. Reprod Biomed Online 2007; 14: 640–9.
16. Fluker M, Grifo J, Leader A et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001; 75: 38–45.
17. Qublan HS, Amarin Z, Tahat YA et al. Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact. Hum Reprod 2006; 21: 640–4.
18. de Klerk C, Heijnen EM, Macklon NS et al. The psychological impact of mild ovarian stimulation combined with single embryo transfer compared with conventional IVF. Hum Reprod 2006; 21: 721–7.
19. Mocanu E, Redmond ML, Hennelly B et al. Odds of ovarian hyperstimulation syndrome (OHSS) – time for reassessment. Hum Fertil (Camb) 2007; 10: 175–81.
20. Kolibianakis EM, Schultze-Mosgau A, Schroer A et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005b; 20: 2887–92.
21. Cousineau TM, Domar AD. Psychological impact of infertility. Best Pract Res Clin Obstet Gynaecol 2007; 21: 293–308.
22. Land JA, Courtar DA, Evers JL. Patient dropout in an assisted reproductive technology program: implications for pregnancy rates. Fertil Steril 1997; 68: 278–81.
23. Olivius C, Friden B, Borg G, Bergh C. Why do couples discontinue in vitro fertilization treatment? A cohort study. Fertil Steril 2004; 81: 258–61.
24. Schroder AK, Katalinic A, Diedrich K, Ludwig M. Cumulative pregnancy rates and drop-out rates in a German IVF programme: 4102 cycles in 2130 patients. Reprod Biomed Online 2004; 8: 600–6.
25. Griesinger G, Dafopoulos K, Schultze-Mosgau A et al. What is the most relevant standard of success in assisted reproduction? Is BESST (birth emphasizing a successful singleton at term) truly the best? Hum Reprod 2004; 19: 1239–41.
26. Twisk M, van der Veen F, Repping S et al. Preferences of subfertile women regarding elective single embryo transfer: additional in vitro fertilization cycles are acceptable, lower pregnancy rates are not. Fertil Steril 2007; 88: 1006–9.
27. Kolibianakis EM, Kalogeropoulou L, Griesinger G et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update 2007a; 13: 445–52.
28. Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod 2007; 22: 2805–13.
29. Engmann L, Diluigi A, Schmidt D et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008; 89: 84–91.
30. Wikland M, Bergh C, Borg K et al. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod 2001; 16: 1676–81.
31. Popovic-Todorovic B, Loft A, Lindhard A et al. A prospective study of predictive factors of ovarian response in ‘standard’ IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod 2003b; 18: 781–7.
32. Kolibianakis EM, Zikopoulos K, Smitz J et al. Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Hum Reprod 2004b; 19: 1525–9.
33. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003; 9: 275–89.
34. Wittemer C, Ohl J, Bailly M et al. Does body mass index of infertile women have an impact on IVF procedure and outcome? J Assist Reprod Genet 2000; 17: 547–52.
35. Ubaldi FM, Rienzi L, Ferrero S et al. Management of poor responders in IVF. Reprod Biomed Online 2005; 10: 235–46.
36. van Hooff MH, Alberda AT, Huisman GJ et al. Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod 1993; 8: 369–73.
37. Kolibianakis EM, Collins J, Tarlatzis BC et al. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006; 12: 651–71.
38. European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001; 16: 644–51.
39. Propst AM, Bates GW, Robinson RD et al. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer. Fertil Steril 2006; 86: 58–63.
40. Wikland M, Borg J, Forsberg AS et al. Human chorionic gonadotrophin self-administered by the subcutaneous route to induce oocyte maturation in an in-vitro fertilization and embryo transfer programme. Hum Reprod 1995; 10: 1667–70.
41. Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev 2004; 3.
42. Williams SC, Oehninger S, Gibbons WE et al. Delaying the initiation of progesterone supplementation results in decreased pregnancy rates after in vitro fertilization: a randomized, prospective study. Fertil Steril 2001; 76: 1140–3.
43. Beckers NG, Macklon NS, Eijkemans MJ et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003; 88: 4186–92.
44. Griesinger G, Venetis ChA, Marx T et al. Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertil Steril 2008, 90 (4): 1055–63.

________________________________________________

1. Шарапова О.В. Письмо МЗ РФ 11 апреля 2003 г. №2510/3797-03-32.
2. Назаренко Т.А.,  Дуринян Э.Р., Чечурова Т.Н. Эндокринное бесплодие у женщин.  Диагностика и лечение. М., 2004.
3. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006; 3: CD001750.
4. Руководство ВОЗ по стандартизованному обследованию и диагностике бесплодных супружеских пар. М.: МЕДпресс, 1997.
5. Кулаков В.И., Корнеева И.Е.  Диагностика и лечение женского бесплодия. В кн.: Практическая гинекология. Под ред. В.И.Кулакова. М., 2002.
6. Verhaak CM, Smeenk JM, van Minnen A et al. A longitudinal, prospective study on emotional adjustment before, during and after consecutive fertility treatment cycles. Hum Reprod 2005; 20: 2253–60.
7. Fauser BC, Devroey P. Why is the clinical acceptance of gonadotropinreleasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 2005; 83: 1607–11.
8. Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians’ second choice? Data from the German national IVF registry. Hum Reprod 2005; 20: 2373–5.
9. River J, Jiang JC, Lahrichi SL et al. Dose relationship between GnRH antagonists and pituitary suppression – GnRH analogues and Reproductive Medicine. Eds. R.G.Edwards, H.Beard, J.P.W.Vermeiden. Hum Reprod 1996; 11 (Suppl. 3): 133–47.
10. Rabinovici J, Rothman P, Monroe SE et al. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. JCEM 1992; 75: 1220–5.
11. Hsueh AJ, Jones PB. Extrapituitary actions of gonadotropin releasing hormone. Endocrinol Rev 1981; 2: 437–61.
12. The ganirelix dose-finding study group. A double-blind, randomized, dose-finding study to assess the efficacy of the GnRH antagonist ganirelix (Org 37642) to prevent premature LH surges in women undergoing controlled ovarian hyperstimulation with recombinant FSH (Puregon). Hum Reprod 1998; 13: 3023–31.
13. Marcus HJ, Marcus DM, Marcus SF. How do infertile couples choose their IVF centers? An internet-based survey. Fertil Steril 2005; 83: 779–81.
14. Lambalk CB, Leader A, Olivennes F et al. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. Hum Reprod 2006; 21: 632–9.
15. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a cochrane review. Reprod Biomed Online 2007; 14: 640–9.
16. Fluker M, Grifo J, Leader A et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001; 75: 38–45.
17. Qublan HS, Amarin Z, Tahat YA et al. Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact. Hum Reprod 2006; 21: 640–4.
18. de Klerk C, Heijnen EM, Macklon NS et al. The psychological impact of mild ovarian stimulation combined with single embryo transfer compared with conventional IVF. Hum Reprod 2006; 21: 721–7.
19. Mocanu E, Redmond ML, Hennelly B et al. Odds of ovarian hyperstimulation syndrome (OHSS) – time for reassessment. Hum Fertil (Camb) 2007; 10: 175–81.
20. Kolibianakis EM, Schultze-Mosgau A, Schroer A et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005b; 20: 2887–92.
21. Cousineau TM, Domar AD. Psychological impact of infertility. Best Pract Res Clin Obstet Gynaecol 2007; 21: 293–308.
22. Land JA, Courtar DA, Evers JL. Patient dropout in an assisted reproductive technology program: implications for pregnancy rates. Fertil Steril 1997; 68: 278–81.
23. Olivius C, Friden B, Borg G, Bergh C. Why do couples discontinue in vitro fertilization treatment? A cohort study. Fertil Steril 2004; 81: 258–61.
24. Schroder AK, Katalinic A, Diedrich K, Ludwig M. Cumulative pregnancy rates and drop-out rates in a German IVF programme: 4102 cycles in 2130 patients. Reprod Biomed Online 2004; 8: 600–6.
25. Griesinger G, Dafopoulos K, Schultze-Mosgau A et al. What is the most relevant standard of success in assisted reproduction? Is BESST (birth emphasizing a successful singleton at term) truly the best? Hum Reprod 2004; 19: 1239–41.
26. Twisk M, van der Veen F, Repping S et al. Preferences of subfertile women regarding elective single embryo transfer: additional in vitro fertilization cycles are acceptable, lower pregnancy rates are not. Fertil Steril 2007; 88: 1006–9.
27. Kolibianakis EM, Kalogeropoulou L, Griesinger G et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update 2007a; 13: 445–52.
28. Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod 2007; 22: 2805–13.
29. Engmann L, Diluigi A, Schmidt D et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008; 89: 84–91.
30. Wikland M, Bergh C, Borg K et al. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod 2001; 16: 1676–81.
31. Popovic-Todorovic B, Loft A, Lindhard A et al. A prospective study of predictive factors of ovarian response in ‘standard’ IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod 2003b; 18: 781–7.
32. Kolibianakis EM, Zikopoulos K, Smitz J et al. Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Hum Reprod 2004b; 19: 1525–9.
33. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003; 9: 275–89.
34. Wittemer C, Ohl J, Bailly M et al. Does body mass index of infertile women have an impact on IVF procedure and outcome? J Assist Reprod Genet 2000; 17: 547–52.
35. Ubaldi FM, Rienzi L, Ferrero S et al. Management of poor responders in IVF. Reprod Biomed Online 2005; 10: 235–46.
36. van Hooff MH, Alberda AT, Huisman GJ et al. Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod 1993; 8: 369–73.
37. Kolibianakis EM, Collins J, Tarlatzis BC et al. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006; 12: 651–71.
38. European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001; 16: 644–51.
39. Propst AM, Bates GW, Robinson RD et al. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer. Fertil Steril 2006; 86: 58–63.
40. Wikland M, Borg J, Forsberg AS et al. Human chorionic gonadotrophin self-administered by the subcutaneous route to induce oocyte maturation in an in-vitro fertilization and embryo transfer programme. Hum Reprod 1995; 10: 1667–70.
41. Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev 2004; 3.
42. Williams SC, Oehninger S, Gibbons WE et al. Delaying the initiation of progesterone supplementation results in decreased pregnancy rates after in vitro fertilization: a randomized, prospective study. Fertil Steril 2001; 76: 1140–3.
43. Beckers NG, Macklon NS, Eijkemans MJ et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003; 88: 4186–92.
44. Griesinger G, Venetis ChA, Marx T et al. Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertil Steril 2008, 90 (4): 1055–63.

Т.В.Янчук